Treatment of the premenstrual syndrome: A double blind placebo controlled cross over study using danazol

David Gilmore, Robert Hawthorn, D. M. Hart
In: Journal of Obstetrics and Gynaecology · 1989 · vol. 9(4) , pp. 318–322 · doi:10.3109/01443618909151073 · W2059670453
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This double-blind placebo-controlled study found that daily danazol treatment significantly improved most common premenstrual symptoms compared to placebo in women with severe premenstrual syndrome.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

SummaryA double blind placebo controlled cross over study was conducted to assess the response of women with severe premenstrual syndrome to treatment with danazol. Daily self assessment of clinical state was measured using the Moos menstrual distress questionnaire. The data were analysed for the Moos symptoms clusters and the most prevalent individual symptoms using the Wilcoxon matched pairs test. Most of the common premenstrual symptoms improved to a statistically greater extent with danazol than with placebo. Despite the incidence of minor side effects danazol, 400 mg/day, proved to be an effective symptomatic treatment for the premenstrual syndrome and should be considered in the management of women with severe symptoms, or in those who are resistant to other forms of treatment.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (3)

References (20)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-10T11:10:24.476570+00:00
License: CC0 · commercial use OK